GRI logo

GRI GRI Bio, Inc.

NASDAQ · Biotechnology · Healthcare

$1.12
+0.00 (+0.00%)

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung d…

Market Cap: $2.45Mwww.gribio.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
—
60d
50
1 mentions
—
90d
52
4 mentions
—
news: 4

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0

Revenue

$0.00
$0.00$33.3K$66.7K$100.0K
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-164.78
$-170.24–$-159.31
2 analysts
FY2026
$-3.88
$-4.13–$-3.63
2 analysts
FY2027
$-2.00
$-3.78–$-0.20
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
W. Marc Hertz
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
-0.59
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-8.18
www.gribio.com